Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock
October 02, 2017 06:52 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
September 29, 2017 07:00 ET
|
Zogenix, Inc.
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in...
Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 08, 2017 16:01 ET
|
Zogenix, Inc.
Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan ...
Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8
August 01, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
June 22, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Present at the Jefferies 2017 Global Healthcare Conference
May 31, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
May 22, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
May 04, 2017 16:01 ET
|
Zogenix, Inc.
Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome; Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of...
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
April 27, 2017 08:01 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
April 27, 2017 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...